Monitor for interim data in H2 2026, which could catalyze investor interest or partnership discussions; watch for future financing activity given limited market cap ($31M) and upcoming trial costs.
Price Chart
Executive Summary
Rein Therapeutics has dosed the first patient in its Phase 2 clinical trial for LTI-03, an inhaled therapy targeting idiopathic pulmonary fibrosis (IPF), following FDA clearance to resume the trial. The study will evaluate safety, tolerability, and effects on lung function in approximately 120 patients, with interim data expected in the second half of 2026.
Key Facts
- First patient dosed in Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis (IPF).
- FDA cleared the company to resume the Phase 2 program after prior hold.
- Trial is randomized, double-blind, placebo-controlled, enrolling ~120 patients across five countries.
- Primary endpoints include safety, tolerability, and changes in lung function (e.g., FVC).
- Interim data expected in second half of 2026; full enrollment expected through mid-2027.
- LTI-03 has Orphan Drug Designation; designed to modulate multiple fibrotic pathways via Caveolin-1 mimicry.
Financial Impact
No immediate financial impact disclosed; trial progression may support future funding or partnerships
Risk Factors
- Clinical trial may fail to show efficacy despite FDA clearance.
- Company may require additional capital, leading to potential dilution.
- Forward-looking statements highlight uncertainty in trial execution and funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3248261 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 7w ago | Press Release | $0.8891 | awaiting T+60 | — | $0.5830 (−34.43%) |
Aug 14, 2026 10w ago | Press Release | $0.8060 | awaiting T+60 | — | $0.5830 (−27.67%) |
Jul 21, 2026 13w ago | Press Release | $0.8948 $0.7546 | ▼ −15.67% | ▼ −19.64% | $0.5830 (−34.85%) |
Jun 8, 2026 20w ago | DEFA14A | $0.9487 $0.7527 | ▼ −20.66% | ▼ −23.71% | $0.5830 (−38.55%) |
May 4, 2026 25w ago | 8-K | $1.02 $0.7680 | ▲ +24.71% | ▲ +27.45% | $0.5830 (+42.84%) |
May 4, 2026 25w ago | 424B5 | $1.02 $0.7580 | ▲ +25.69% | ▲ +27.54% | $0.5830 (+42.84%) |
May 1, 2026 25w ago | Press Release | $1.03 $0.7818 | ▲ +24.10% | ▲ +27.17% | $0.5830 (+43.40%) |
Apr 29, 2026 25w ago | Press Release | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.5830 (−54.27%) |
Apr 28, 2026 25w ago | S-1 | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.5830 (−54.27%) |
Apr 27, 2026 26w ago | 10-K/A | $1.49 $0.8400 | ▼ −43.62% | ▼ −48.40% | $0.5830 (−60.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers